loader

NexImmune Inc.

NASDAQ:NEXI
Featured Articles and Interviews
Press Releases

Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.

Interactive Chart

×